Frederic Viret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Frederic Viret has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Dominique Genre
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
5 shared publications - Patrice Viens
Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France
5 shared publications - Marc Ychou
Department of Medical oncology, Montpellier Cancer Institute (ICM), Montpellier University , Montpellier 34298 Cedex 5
4 shared publications C Chabannon
Department of Gene Therapy, Institut Paoli-Calmettes, Marseille, France
3 shared publicationsD Maraninchi
Department of Medicine, Institut Paoli-Calmettes, Marseille, France
3 shared publicationsG Gravis
Department of Medicine, Institut Paoli-Calmettes, Marseille, France
3 shared publications
Latest Publications
- 21 January 2009
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (4) , 856-860
Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients
Combining conventional systemic chemotherapy with the angiogenesis inhibitor bevacizumab is now recommended as a first treatment for metastatic colorectal neoplasms. The risk for short-term postoperative complications related to bevacizumab has been assessed. Late postoperative complications related to bevacizumab have also been suggested by preliminary reports. We reviewed a cohort of 142 patients with previous surgery for primary colonic or rectal tumor and without evidence of local recurrence, receiving bevacizumab for metastatic disease. Four patients experienced a late surgical site complication related to bevacizumab. Common features were rectal location, low anastomosis, and preoperative irradiation. Combining these three factors, the risk of a bevacizumab-related complication was 4 in 27 (14.8%); if previous history of postoperative leakage was reported, the risk was raised to 2 in 4. No complications occurred in colonic location or the non-irradiated patients. The mechanism of these complications could be ischemic lesion in post-irradiated tissues involving anastomoses. We conclude that angiogenesis inhibitors should be carefully considered for patients having low colorectal anastomosis and previous irradiation.
- 21 January 2009
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (4) , 856-860
Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients
Combining conventional systemic chemotherapy with the angiogenesis inhibitor bevacizumab is now recommended as a first treatment for metastatic colorectal neoplasms. The risk for short-term postoperative complications related to bevacizumab has been assessed. Late postoperative complications related to bevacizumab have also been suggested by preliminary reports. We reviewed a cohort of 142 patients with previous surgery for primary colonic or rectal tumor and without evidence of local recurrence, receiving bevacizumab for metastatic disease. Four patients experienced a late surgical site complication related to bevacizumab. Common features were rectal location, low anastomosis, and preoperative irradiation. Combining these three factors, the risk of a bevacizumab-related complication was 4 in 27 (14.8%); if previous history of postoperative leakage was reported, the risk was raised to 2 in 4. No complications occurred in colonic location or the non-irradiated patients. The mechanism of these complications could be ischemic lesion in post-irradiated tissues involving anastomoses. We conclude that angiogenesis inhibitors should be carefully considered for patients having low colorectal anastomosis and previous irradiation.
- Open Access
- 15 January 2009
- Published by EDP Sciences in médecine/sciences
- Vol. 25, 13-21
Cancer colorectaux métastatiques et thérapies ciblées anti-EGFR
Colorectal cancer (CRC) (CRC) is one of the leading causes of mortality and accounts for approximately 200 000 deaths per year in Europe and the USA. Chemotherapy and radiotherapy have established roles in the treatment of colorectal cancer and can contribute to cure rate, prolongation of survival, reduction of local rates of recurrence and enhanced quality of life in patients with advanced disease. However, over the past few years there have been major advances in our understanding of the molecular basis of this tumour and its progression from adenoma to carcinoma that hold potential for translation into novel strategies for the treatment of CRC. Furthermore, newer agents directed against different intracellular targets have also been shown to be efficacious in CRC treatment. Such improvements should continue to lead to increased cure rates in early disease and better overall survival in advanced cases.
- 15 January 2009
- Published by EDP Sciences in médecine/sciences
- Vol. 25, 13-21
Open AccessCancer colorectaux métastatiques et thérapies ciblées anti-EGFR
Colorectal cancer (CRC) (CRC) is one of the leading causes of mortality and accounts for approximately 200 000 deaths per year in Europe and the USA. Chemotherapy and radiotherapy have established roles in the treatment of colorectal cancer and can contribute to cure rate, prolongation of survival, reduction of local rates of recurrence and enhanced quality of life in patients with advanced disease. However, over the past few years there have been major advances in our understanding of the molecular basis of this tumour and its progression from adenoma to carcinoma that hold potential for translation into novel strategies for the treatment of CRC. Furthermore, newer agents directed against different intracellular targets have also been shown to be efficacious in CRC treatment. Such improvements should continue to lead to increased cure rates in early disease and better overall survival in advanced cases.
- 1 October 2008
- Vol. 100 (5) , 416-9
Multicystic peritoneal mesothelioma: report of three cases.
Multicystic peritoneal mesothelioma is a rare lesion occurring mainly in women in a reproductive age. Its pathogenesis is unclear. We report three cases of multicystic peritoneal mesothelioma in patients that were 28, 38 and 47 years of age (one male, two females). A history of abdominal surgery was reported in two cases. Explorative laparotomy was presumptive of a pseudomyxoma peritoni in two cases, and hyperthermic intraperitoneal chemotherapy was performed. Histological examination demonstrated multicystic lesions with mesothelial cells lining confirmed by immunohistochemical analysis. Unusual findings such as hyperplasia, hobnail features, cytoplasmic vacuolisation and papillary pattern were occasionally noted. The clinical presentation, pathogenesis and pathologic features including differential diagnosis of multicystic peritoneal mesothelioma are discussed.
- 1 October 2008
- Vol. 100 (5) , 416-9
Multicystic peritoneal mesothelioma: report of three cases.
Multicystic peritoneal mesothelioma is a rare lesion occurring mainly in women in a reproductive age. Its pathogenesis is unclear. We report three cases of multicystic peritoneal mesothelioma in patients that were 28, 38 and 47 years of age (one male, two females). A history of abdominal surgery was reported in two cases. Explorative laparotomy was presumptive of a pseudomyxoma peritoni in two cases, and hyperthermic intraperitoneal chemotherapy was performed. Histological examination demonstrated multicystic lesions with mesothelial cells lining confirmed by immunohistochemical analysis. Unusual findings such as hyperplasia, hobnail features, cytoplasmic vacuolisation and papillary pattern were occasionally noted. The clinical presentation, pathogenesis and pathologic features including differential diagnosis of multicystic peritoneal mesothelioma are discussed.
- Open Access
- 10 June 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 169
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity. We analyzed tumor tissues from 32 EGFR-positive mCRC patients receiving cetuximab/irinotecan combination and evaluable for treatment response. EGFR copy number was quantified by fluorescence in situ hybridization (FISH). KRAS exon 1 and EGFR exons coding for extracellular regions were sequenced. Nine patients experienced an objective response (partial response) and 23 were considered as nonresponders (12 with stable disease and 11 with progressive disease). There was no EGFR amplification found, but high polysomy was noted in 2 patients, both of which were cetuximab responders. No EGFR mutations were found but a variant of exon 13 (R521K) was observed in 12 patients, 11 of which achieved objective response or stable disease. Progression-free and overall survivals were significantly better in patients with this EGFR exon 13 variant. KRAS mutations were found in 14 cases. While there was a trend for an increased KRAS mutation frequency in nonresponder patients (12 mutations out of 23, 52%) as compared to responder patients (2 out of 9, 22%), authentic tumor response or long-term disease stabilization was found in KRAS mutated patients. This preliminary study suggests that: an increase in EGFR copy number may be associated with cetuximab response but is a rare event in CRC, KRAS mutations are associated with low response rate but do not preclude any cetuximab-based combination efficacy and EGFR exon 13 variant (R521K) may predict for cetuximab benefit.
- 10 June 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 169
Open AccessA polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity. We analyzed tumor tissues from 32 EGFR-positive mCRC patients receiving cetuximab/irinotecan combination and evaluable for treatment response. EGFR copy number was quantified by fluorescence in situ hybridization (FISH). KRAS exon 1 and EGFR exons coding for extracellular regions were sequenced. Nine patients experienced an objective response (partial response) and 23 were considered as nonresponders (12 with stable disease and 11 with progressive disease). There was no EGFR amplification found, but high polysomy was noted in 2 patients, both of which were cetuximab responders. No EGFR mutations were found but a variant of exon 13 (R521K) was observed in 12 patients, 11 of which achieved objective response or stable disease. Progression-free and overall survivals were significantly better in patients with this EGFR exon 13 variant. KRAS mutations were found in 14 cases. While there was a trend for an increased KRAS mutation frequency in nonresponder patients (12 mutations out of 23, 52%) as compared to responder patients (2 out of 9, 22%), authentic tumor response or long-term disease stabilization was found in KRAS mutated patients. This preliminary study suggests that: an increase in EGFR copy number may be associated with cetuximab response but is a rare event in CRC, KRAS mutations are associated with low response rate but do not preclude any cetuximab-based combination efficacy and EGFR exon 13 variant (R521K) may predict for cetuximab benefit.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 6524
Systematic versus on-request patients' access to medical files: Randomized trial—Influence on anxiety, quality of life and treatment satisfaction in cancer patients
6524 Background: Most cancer patients (pts) wish to be fully informed about their disease and treatments. The aim of this study was to determine whether giving unlimited and systematic access to the Medical File (MF) for cancer pts could modify their anxiety, quality of life and treatment satisfaction. We conducted a randomized study to investigate the effect of systematic versus on request access to the MF on the pt. Methods: Pts with breast, colon cancer and lymphoma treated by chemotherapy in an outpatient setting were offered to participate in this study, 336 patients were randomly assigned to receive systematically or not a copy of their complete MF. The primary outcome measure was anxiety (state trait anxiety Inventory), secondary were quality of life (QLQ-C30) and pts' satisfaction (specific auto questionnaire). Results: Anxiety levels did not increase for pts who possessed complete MF at study entry and was equivalent for both groups during and at the end of treatment. Global quality of life was not different between the two groups, 90% of the whole were rather or totally satisfied with information. Higher proportion of pts who had systematic access to their MF were sufficiently informed compared to pts who did not have systematic access (65.6% vs 53.5% p=0.066). Of all pts with systematic access to their MF, 81.5% were rather or completely satisfied to possess MF, 76.3% read it and more than 82.2% had understood information provided. Access to MF did not increase anxiety level for 60% and 73.3% did not regret to possess their MF. To the question “do you have some information you had wished to ignore?” 77% answer “not at all” and 70.4% would choose the same option again. Probability of being completely satisfied with treatment information as well as probability to consider being sufficiently informed increased when pts had systematic access to their MF. Conclusions: Full and automatic access to the MF is one way to improve information delivered to pts. Anxiety did not increase when pts had unlimited access to their MF and they would choose this access again after having experienced it. A significant higher proportion of pts were totally satisfied with information delivered when they have had an unlimited access to MF. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 6524
Systematic versus on-request patients' access to medical files: Randomized trial—Influence on anxiety, quality of life and treatment satisfaction in cancer patients
6524 Background: Most cancer patients (pts) wish to be fully informed about their disease and treatments. The aim of this study was to determine whether giving unlimited and systematic access to the Medical File (MF) for cancer pts could modify their anxiety, quality of life and treatment satisfaction. We conducted a randomized study to investigate the effect of systematic versus on request access to the MF on the pt. Methods: Pts with breast, colon cancer and lymphoma treated by chemotherapy in an outpatient setting were offered to participate in this study, 336 patients were randomly assigned to receive systematically or not a copy of their complete MF. The primary outcome measure was anxiety (state trait anxiety Inventory), secondary were quality of life (QLQ-C30) and pts' satisfaction (specific auto questionnaire). Results: Anxiety levels did not increase for pts who possessed complete MF at study entry and was equivalent for both groups during and at the end of treatment. Global quality of life was not different between the two groups, 90% of the whole were rather or totally satisfied with information. Higher proportion of pts who had systematic access to their MF were sufficiently informed compared to pts who did not have systematic access (65.6% vs 53.5% p=0.066). Of all pts with systematic access to their MF, 81.5% were rather or completely satisfied to possess MF, 76.3% read it and more than 82.2% had understood information provided. Access to MF did not increase anxiety level for 60% and 73.3% did not regret to possess their MF. To the question “do you have some information you had wished to ignore?” 77% answer “not at all” and 70.4% would choose the same option again. Probability of being completely satisfied with treatment information as well as probability to consider being sufficiently informed increased when pts had systematic access to their MF. Conclusions: Full and automatic access to the MF is one way to improve information delivered to pts. Anxiety did not increase when pts had unlimited access to their MF and they would choose this access again after having experienced it. A significant higher proportion of pts were totally satisfied with information delivered when they have had an unlimited access to MF. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 4075
Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)
4075 Background: LVFU combinations with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) have shown to improve outcome of advanced colorectal cancer. However, the standard doses of these regimens applied to patients with initially unresectable LMCRC have shown poor rates of resectability. The aim of this randomized trial was to select the most efficacious experimental intensified chemotherapy arm among high dose (HD) FOLFIRI (Iri 260mg/m²), FOLFOX-7 (Ox 130mg/m²) and FOLFIRINOX (Iri 180mg/m² + Ox 85mg/m²) in patients (pts) with initially unresectable or potentially resectable LMCRC. Methods: Main inclusion criteria: non pretreated potentially resectable LM (class II) or unresectable LM without extra-hepatic metastases except 1 to 3 resectable lung metastases. Pts were randomized to either standard (A/B) or intensified chemotherapy (C/D/E): FOLFIRI (A), FOLFOX-4 (B), FOLFIRI-HD (C), FOLFOX-7 (D), or FOLFIRINOX (E). In arms C/D/E, prophylactic G-CSF was given. Primary endpoint was objective response rate (RR) (RECIST) after Cycle 4. Secondary endpoints were safety, R0 surgical resection, best RR, PFS and OS. A total of 120 pts randomized in a 1:1:2:2:2 ratio were necessary to select an experimental arm (2-stage Fleming design, p0=0.40, p1=0.60, alpha=10%, beta=20%). Results: Between Oct 2004 and Aug 2007, 125 pts from 17 centers were randomized, 122 were eligible and treated: 30 (A+B), 32 (C), 30 (D) and 30 (E). Reasons for unresectability were well balanced: 45% pts had less than 30% of remaining healthy liver, 20% had vascular contact, and 35% were class II. Respectively 20, 12, 23 and 17% had lung metastases in arms (A+B), C, D and E. Grade 3/4 toxicities during the first 4 cycles in Arms (A+B)/C/D/E were respectively: neutropenia (24, 19, 10, 23%) diarrhea (0, 6, 3, 23%), mucositis (0, 3, 0, 7%), vomiting (7, 9, 0, 3%), neurotoxicity (0, 0, 10, 3%). The objective RR after 4 cycles in Arms (A+B)/C/D/E were: 43, 50, 50 and 52%. Conclusions: These results suggest an improvement in early RR for LMCRC with these intensified chemotherapy regimen with acceptable toxicity. Major secondary endpoints such as R0 surgical resection will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology, sanofi-aventis sanofi-aventis
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 4075
Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)
4075 Background: LVFU combinations with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) have shown to improve outcome of advanced colorectal cancer. However, the standard doses of these regimens applied to patients with initially unresectable LMCRC have shown poor rates of resectability. The aim of this randomized trial was to select the most efficacious experimental intensified chemotherapy arm among high dose (HD) FOLFIRI (Iri 260mg/m²), FOLFOX-7 (Ox 130mg/m²) and FOLFIRINOX (Iri 180mg/m² + Ox 85mg/m²) in patients (pts) with initially unresectable or potentially resectable LMCRC. Methods: Main inclusion criteria: non pretreated potentially resectable LM (class II) or unresectable LM without extra-hepatic metastases except 1 to 3 resectable lung metastases. Pts were randomized to either standard (A/B) or intensified chemotherapy (C/D/E): FOLFIRI (A), FOLFOX-4 (B), FOLFIRI-HD (C), FOLFOX-7 (D), or FOLFIRINOX (E). In arms C/D/E, prophylactic G-CSF was given. Primary endpoint was objective response rate (RR) (RECIST) after Cycle 4. Secondary endpoints were safety, R0 surgical resection, best RR, PFS and OS. A total of 120 pts randomized in a 1:1:2:2:2 ratio were necessary to select an experimental arm (2-stage Fleming design, p0=0.40, p1=0.60, alpha=10%, beta=20%). Results: Between Oct 2004 and Aug 2007, 125 pts from 17 centers were randomized, 122 were eligible and treated: 30 (A+B), 32 (C), 30 (D) and 30 (E). Reasons for unresectability were well balanced: 45% pts had less than 30% of remaining healthy liver, 20% had vascular contact, and 35% were class II. Respectively 20, 12, 23 and 17% had lung metastases in arms (A+B), C, D and E. Grade 3/4 toxicities during the first 4 cycles in Arms (A+B)/C/D/E were respectively: neutropenia (24, 19, 10, 23%) diarrhea (0, 6, 3, 23%), mucositis (0, 3, 0, 7%), vomiting (7, 9, 0, 3%), neurotoxicity (0, 0, 10, 3%). The objective RR after 4 cycles in Arms (A+B)/C/D/E were: 43, 50, 50 and 52%. Conclusions: These results suggest an improvement in early RR for LMCRC with these intensified chemotherapy regimen with acceptable toxicity. Major secondary endpoints such as R0 surgical resection will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology, sanofi-aventis sanofi-aventis
- 27 February 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (7) , 669-675
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol
Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion). Five-day CI induces grade IV mucositis at high doses (MTD6 weeks. From August 1998 to April 2002, 49 patients were included. Forty-three patients have completed one course and 15 have received two cycles. One patient treated at level 7 mg/m2/day died of sepsis. Median duration of grade IV neutropenia was 9 days. Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days.
- 27 February 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (7) , 669-675
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol
Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion). Five-day CI induces grade IV mucositis at high doses (MTD6 weeks. From August 1998 to April 2002, 49 patients were included. Forty-three patients have completed one course and 15 have received two cycles. One patient treated at level 7 mg/m2/day died of sepsis. Median duration of grade IV neutropenia was 9 days. Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 3502
A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)
3502 Background: LV5FU2+CPT-11 has shown more activity than LV5FU2 alone in first line metastatic colorectal cancer. This adjuvant trial evaluated the addition of CPT-11 to LV5FU2 in terms of Event-Free Survival (EFS) and safety in colorectal cancer patients (pts) at a high risk of relapse. Methods: Colon cancer pts with postoperative N2 or N1 detected by occlusion/perforation were randomized to either: A: LV5FU2 (leucovorin 200mg/m2 as a 2-h infusion, 5-FU 400mg/m2 bolus and 600mg/m2 22-h continuous infusion, d1–2) or B: LV5FU2+CPT-11 (irinotecan 180mg/m2 90-min infusion d1+LV5FU2) fortnightly for 12 cycles without any support of growth factors. Pts were stratified by center, type of detection, delay from surgery to chemotherapy (≤28d; >28d) and age (<65y;≥65y). A 0.64 hazard ratio was deduced from an expected change in 3-year EFS from 45% to 60% with 5% two-sided alpha and 85% power. ITT survival analysis used the Logrank test. Results: 400 pts were randomized 1:1 in 75 centers between 11/98 and 09/02. Median follow-up is 36 months. More T3/T4 (p<0.017), more 15+ positives nodes (p<0.014), more vascular invasion (p<0.031), and more perineural involvement (p80% for 95% and 77% in arms A and B (p80% for 70% pts. More NCI G3–4 neutropenia in arm B (4% vs. 28%pts, p<0.001) is related to the absence of G-CSF support. In spite of only 97% necessary events observed, there was no significant difference in EFS rates between the 2 treatment arms. Conclusions: The two arms were unbalanced for important prognostic factors. Adjuvant LV5FU2+CPT-11 as compared to LV5FU2 alone is associated with more G3–4 neutropenia. These preliminary results show no improvement between the 2 arms in terms of EFS in the ITT analysis. Final analysis will be presented with more follow-up. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 3502
A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)
3502 Background: LV5FU2+CPT-11 has shown more activity than LV5FU2 alone in first line metastatic colorectal cancer. This adjuvant trial evaluated the addition of CPT-11 to LV5FU2 in terms of Event-Free Survival (EFS) and safety in colorectal cancer patients (pts) at a high risk of relapse. Methods: Colon cancer pts with postoperative N2 or N1 detected by occlusion/perforation were randomized to either: A: LV5FU2 (leucovorin 200mg/m2 as a 2-h infusion, 5-FU 400mg/m2 bolus and 600mg/m2 22-h continuous infusion, d1–2) or B: LV5FU2+CPT-11 (irinotecan 180mg/m2 90-min infusion d1+LV5FU2) fortnightly for 12 cycles without any support of growth factors. Pts were stratified by center, type of detection, delay from surgery to chemotherapy (≤28d; >28d) and age (<65y;≥65y). A 0.64 hazard ratio was deduced from an expected change in 3-year EFS from 45% to 60% with 5% two-sided alpha and 85% power. ITT survival analysis used the Logrank test. Results: 400 pts were randomized 1:1 in 75 centers between 11/98 and 09/02. Median follow-up is 36 months. More T3/T4 (p<0.017), more 15+ positives nodes (p<0.014), more vascular invasion (p<0.031), and more perineural involvement (p80% for 95% and 77% in arms A and B (p80% for 70% pts. More NCI G3–4 neutropenia in arm B (4% vs. 28%pts, p<0.001) is related to the absence of G-CSF support. In spite of only 97% necessary events observed, there was no significant difference in EFS rates between the 2 treatment arms. Conclusions: The two arms were unbalanced for important prognostic factors. Adjuvant LV5FU2+CPT-11 as compared to LV5FU2 alone is associated with more G3–4 neutropenia. These preliminary results show no improvement between the 2 arms in terms of EFS in the ITT analysis. Final analysis will be presented with more follow-up. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 4118
Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study
4118 Background: The survival of patients (pts) with locally advanced or metastatic pancreatic cancer could be improved by the addition of P to standard chemotherapy with G. Methods: The primary objective was to compare time to treatment failure (TTF) of pts treated with GP versus G. Secondary objectives were to compare toxicity, overall survival time (OST), quality-adjusted time without symptoms or toxicity (Q-TWiST analysis), and quality of life (EORTC QLQ-C30 questionnaire) between arms and to assess objective response rate (ORR) and duration of response in the two arms. Chemonaive pts age 18–75 yrs with histologically proven stage III or IV pancreatic cancer were randomized to receive G 1000 mg/m2/wk × 3 plus P 75 mg/m2 on day 15 every 4 wks (GP arm) or G 1000 mg/m2/wk × 7 followed by 1 week of rest for cycle 1, and then G at the same dose × 3 every 4 wks (G arm). Results: From July 2000 to August 2002, 83 pts (42 GP, 41 G) received a median of 4 and 3 cycles for GP and G, respectively. Baseline characteristics (GP/G) were stage III disease in 8/9 and stage IV in 34/32 pts; median age of 61.5 yrs/63 yrs; and WHO PS 0–1 in 32/34 and PS 2 in 10/7 pts. The median TTF was 65 days (95% CI, 52–145) for GP and 76 days (95% CI, 52–111) for G (p=.67). Respective median OST was 241 days (95% CI, 130–295) and 201 days (95% CI, 133–326) (p=.73). Additionally, 7% of GP pts had PR and 48% had SD, while 5% of G pts had PR and 46% had SD. Q-TWiST results did not differ significantly between the two arms. Median dose intensities were 92% G and 69% P (GP) and 94% (G). The main CTC grade 3/4 toxicities (% pts) for GP/G included neutropenia (56/40), anemia (37/28), nausea (15/5), vomiting (7/3), anorexia (2/0); in particular, the incidence of grade 3/4 thrombocytopenia (34/13; p=.03) and asthenia (5/10; p=.04) differed significantly between arms. Conclusions: The addition of P to G does not appear to improve the prognosis of pts with locally advanced or metastatic pancreatic cancer. Other gemcitabine-based combinations should be evaluated. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 4118
Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study
4118 Background: The survival of patients (pts) with locally advanced or metastatic pancreatic cancer could be improved by the addition of P to standard chemotherapy with G. Methods: The primary objective was to compare time to treatment failure (TTF) of pts treated with GP versus G. Secondary objectives were to compare toxicity, overall survival time (OST), quality-adjusted time without symptoms or toxicity (Q-TWiST analysis), and quality of life (EORTC QLQ-C30 questionnaire) between arms and to assess objective response rate (ORR) and duration of response in the two arms. Chemonaive pts age 18–75 yrs with histologically proven stage III or IV pancreatic cancer were randomized to receive G 1000 mg/m2/wk × 3 plus P 75 mg/m2 on day 15 every 4 wks (GP arm) or G 1000 mg/m2/wk × 7 followed by 1 week of rest for cycle 1, and then G at the same dose × 3 every 4 wks (G arm). Results: From July 2000 to August 2002, 83 pts (42 GP, 41 G) received a median of 4 and 3 cycles for GP and G, respectively. Baseline characteristics (GP/G) were stage III disease in 8/9 and stage IV in 34/32 pts; median age of 61.5 yrs/63 yrs; and WHO PS 0–1 in 32/34 and PS 2 in 10/7 pts. The median TTF was 65 days (95% CI, 52–145) for GP and 76 days (95% CI, 52–111) for G (p=.67). Respective median OST was 241 days (95% CI, 130–295) and 201 days (95% CI, 133–326) (p=.73). Additionally, 7% of GP pts had PR and 48% had SD, while 5% of G pts had PR and 46% had SD. Q-TWiST results did not differ significantly between the two arms. Median dose intensities were 92% G and 69% P (GP) and 94% (G). The main CTC grade 3/4 toxicities (% pts) for GP/G included neutropenia (56/40), anemia (37/28), nausea (15/5), vomiting (7/3), anorexia (2/0); in particular, the incidence of grade 3/4 thrombocytopenia (34/13; p=.03) and asthenia (5/10; p=.04) differed significantly between arms. Conclusions: The addition of P to G does not appear to improve the prognosis of pts with locally advanced or metastatic pancreatic cancer. Other gemcitabine-based combinations should be evaluated. No significant financial relationships to disclose.
- 18 November 2003
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (11) , 1059-1064
Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy
- 18 November 2003
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (11) , 1059-1064
Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy